Search research articles
Contact Us
Filters
Showing results (691-700 of 928) with videos related to
Page
of 93
Sort By:
Journal of the American College of Cardiology
|
August 31, 2019
Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery
Shaun G Goodman, Philip E Aylward, Michael Szarek, et al.
BMJ Open
|
July 28, 2019
Subclinical thyroid dysfunction and depressive symptoms: protocol for a systematic review and individual participant data meta-analysis of prospective cohort studies
Lea Wildisen, Elisavet Moutzouri, Shanthi Beglinger, et al.
Thrombosis and Haemostasis
|
December 8, 2007
The influence of established genetic variation in the haemostatic system on clinical restenosis after percutaneous coronary interventions
Douwe Pons, Pascalle S Monraats, Moniek P M de Maat, et al.
BMC Medicine
|
November 11, 2016
Renal function estimation and Cockroft-Gault formulas for predicting cardiovascular mortality in population-based, cardiovascular risk, heart failure and post-myocardial infarction cohorts: The Heart 'OMics' in AGEing (HOMAGE) and the high-risk myocardial infarction database initiatives
João Pedro Ferreira, Nicolas Girerd, Pierpaolo Pellicori, et al.
American Heart Journal
|
December 3, 2014
Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial
Gregory G Schwartz, Laurence Bessac, Lisa G Berdan, et al.
European Heart Journal
|
November 17, 2019
Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: an ODYSSEY OUTCOMES trial analysis
Peter R Sinnaeve, Gregory G Schwartz, Daniel M Wojdyla, et al.
The New England Journal of Medicine
|
November 8, 2018
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
Gregory G Schwartz, P Gabriel Steg, Michael Szarek, et al.
American Heart Journal
|
July 17, 2025
Design and rationale of the HARTc 2.0 trial: A multicenter randomized controlled study on the impact of point-of-care high-sensitivity cardiac troponin-I testing in prehospital acute coronary syndrome triage on diagnosis and cost-effectiveness
Anne Catherine M H van der Lande, Nina M Diederiks, Enrico R de Koning, et al.
The Journal of Clinical Endocrinology and Metabolism
|
February 26, 2022
No Effect of Levothyroxine on Hemoglobin in Older Adults With Subclinical Hypothyroidism: Pooled Results From 2 Randomized Controlled Trials
Robert S Du Puy, Rosalinde K E Poortvliet, Simon P Mooijaart, et al.
Circulation. Genomic and Precision Medicine
|
November 4, 2021
Identification of Functional Genetic Determinants of Cardiac Troponin T and I in a Multiethnic Population and Causal Associations With Atrial Fibrillation
Yunju Yang, Traci M Bartz, Michael R Brown, et al.
Page
of 93
Search research articles
Search
Showing results (691-700 of 928) with videos related to
Sort By:
Page
of 93
Journal of the American College of Cardiology
|
August 31, 2019
Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery
Shaun G Goodman, Philip E Aylward, Michael Szarek, et al.
BMJ Open
|
July 28, 2019
Subclinical thyroid dysfunction and depressive symptoms: protocol for a systematic review and individual participant data meta-analysis of prospective cohort studies
Lea Wildisen, Elisavet Moutzouri, Shanthi Beglinger, et al.
Thrombosis and Haemostasis
|
December 8, 2007
The influence of established genetic variation in the haemostatic system on clinical restenosis after percutaneous coronary interventions
Douwe Pons, Pascalle S Monraats, Moniek P M de Maat, et al.
BMC Medicine
|
November 11, 2016
Renal function estimation and Cockroft-Gault formulas for predicting cardiovascular mortality in population-based, cardiovascular risk, heart failure and post-myocardial infarction cohorts: The Heart 'OMics' in AGEing (HOMAGE) and the high-risk myocardial infarction database initiatives
João Pedro Ferreira, Nicolas Girerd, Pierpaolo Pellicori, et al.
American Heart Journal
|
December 3, 2014
Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial
Gregory G Schwartz, Laurence Bessac, Lisa G Berdan, et al.
European Heart Journal
|
November 17, 2019
Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: an ODYSSEY OUTCOMES trial analysis
Peter R Sinnaeve, Gregory G Schwartz, Daniel M Wojdyla, et al.
The New England Journal of Medicine
|
November 8, 2018
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
Gregory G Schwartz, P Gabriel Steg, Michael Szarek, et al.
American Heart Journal
|
July 17, 2025
Design and rationale of the HARTc 2.0 trial: A multicenter randomized controlled study on the impact of point-of-care high-sensitivity cardiac troponin-I testing in prehospital acute coronary syndrome triage on diagnosis and cost-effectiveness
Anne Catherine M H van der Lande, Nina M Diederiks, Enrico R de Koning, et al.
The Journal of Clinical Endocrinology and Metabolism
|
February 26, 2022
No Effect of Levothyroxine on Hemoglobin in Older Adults With Subclinical Hypothyroidism: Pooled Results From 2 Randomized Controlled Trials
Robert S Du Puy, Rosalinde K E Poortvliet, Simon P Mooijaart, et al.
Circulation. Genomic and Precision Medicine
|
November 4, 2021
Identification of Functional Genetic Determinants of Cardiac Troponin T and I in a Multiethnic Population and Causal Associations With Atrial Fibrillation
Yunju Yang, Traci M Bartz, Michael R Brown, et al.
Page
of 93